CANNASOUL ANALYTICS LTD. AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENTInvestors' Rights Agreement • November 6th, 2023 • Synaptogenix, Inc. • Pharmaceutical preparations • Tel-Aviv
Contract Type FiledNovember 6th, 2023 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 24th day of October 2023, by and among Cannasoul Analytics Ltd.., Reg. No. 515782894, a company incorporated under the laws of the State of Israel (the “Company”), the founders of the Company listed on Schedule A attached hereto (the “Founders”), and the investors listed on Schedule B attached hereto (each, an “Investor” and collectively, the “Investors”, and together with the Founders, the “Shareholders”).
COLLABORATION AGREEMENTCollaboration Agreement • November 6th, 2023 • Synaptogenix, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 6th, 2023 Company Industry JurisdictionThis Collaboration Agreement (“Agreement”) is effective as of the date of last signature below (“Effective Date”) and is by and between Synaptogenix, Inc., a Delaware corporation with its principal place of business at 1185 Avenue Of The Americas, 3rd Floor, New York, NY 10036, United States ("Synaptogenix"), and Cannasoul Analytics Ltd., a company duly incorporated under the laws of the State of Israel, registration number 515782894, having its principal offices at 9 Tarshish Street, Caesarea, Israel (“Cannasoul”). Synaptogenix and Cannasoul are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
SHARE PURCHASE AGREEMENTShare Purchase Agreement • November 6th, 2023 • Synaptogenix, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 6th, 2023 Company IndustryThis Share Purchase Agreement (this “Agreement”) is made as of October 31, 2023, by and among Cannasoul Analytics Ltd., a company duly incorporated under the laws of the State of Israel, registration number 515782894, having its principal offices at 9 Tarshish Street, Caesarea, Israel (the “Company”), and the Investor set forth in Schedule A (the “Investor”). Each of the Company and the Investors individually referred hereinafter as a “Party” and jointly as the “Parties”.